(Q37690351)

English

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers

scientific article published on January 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers (English)

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

1 reference

based on heuristic

inferred from title

Benjamin Haibe-Kains

17

object named as

Benjamin Haibe-Kains

0 references

19

object named as

Luca Gianni

0 references

Libero Santarpia

object named as

Libero Santarpia

12

0 references

object named as

Thomas Karn

3

0 references

author name string

Giampaolo Bianchini

1

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Lajos Pusztai

2

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Takayuki Iwamoto

4

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Achim Rody

5

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Catherine Kelly

6

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Volkmar Müller

7

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Schmidt Schmidt

8

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Yuan Qi

9

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Uwe Holtrich

10

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Sven Becker

11

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Angelica Fasolo

13

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Gianluca Del Conte

14

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Milvia Zambetti

15

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Christos Sotiriou

16

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

W Fraser Symmans

18

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

publication date

1 January 2013

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Breast Cancer Research

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

15

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

5

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

R86

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978752

23 August 2017

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978752

23 August 2017

A three-gene model to robustly identify breast cancer molecular subtypes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978752

23 August 2017

Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978752

23 August 2017

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978752

23 August 2017

Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978752

23 August 2017

Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978752

23 August 2017

Breast cancer adjuvant therapy: time to consider its time-dependent effects.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978752

23 August 2017

A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978752

23 August 2017

Genomic index of sensitivity to endocrine therapy for breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978752

23 August 2017

Variables with time-varying effects and the Cox model: some statistical concepts illustrated with a prognostic factor study in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978752

23 August 2017

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978752

23 August 2017

Analysis of gene expression data using BRB-ArrayTools.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978752

23 August 2017

Supervised risk predictor of breast cancer based on intrinsic subtypes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978752

23 August 2017

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978752

23 August 2017

Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978752

23 August 2017

Lung metastasis genes couple breast tumor size and metastatic spread.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978752

23 August 2017

Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978752

23 August 2017

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978752

23 August 2017

Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978752

23 August 2017

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978752

23 August 2017

A gene-expression signature as a predictor of survival in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978752

23 August 2017

Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978752

6 September 2017

Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978752

23 June 2018

Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978752

23 June 2018

A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978752

1 September 2018

Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978752

1 September 2018

Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978752

1 September 2018

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978752

1 September 2018

The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978752

1 September 2018

Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978752

1 September 2018

The humoral immune system has a key prognostic impact in node-negative breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24060333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hazard function estimators: a simulation study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24060333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/24060333

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/BCR3481

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37690351&oldid=2200806641"